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Since there had been no previous studies of alterations in insulin sensitivity, glucose-stimulated insulin secretion,
beta cell function and glucose effectiveness during the development of non-diabetic hyperglycemia in Asian populations,
we conducted a longitudinal study of such changes in 244 Japanese adults with normal glucose tolerance (median BMI
23.3 kg/m2 and age 51 yrs). The median follow-up period was 3.3 yrs. One hundred and eighty-two subjects maintained
normal glucose tolerance (nonprogressors). After excluding the 3 subjects who progressed to diabetes, we analyzed the
59 who developed non-diabetic hyperglycemia (progressors), of which 31 progressed to impaired fasting glucose and
28 to impaired glucose tolerance. Whole body insulin sensitivity was estimated by ISIMatsuda, glucose-stimulated insulin
secretion by [δIRI0-30/δPG0-30] and Stumvoll indices, hepatic insulin sensitivity by quantitative insulin sensitivity check index
(QUICKI) and 1/fasting IRI, beta cell function by oral disposition index (DIO) ([δIRI0-30/δPG0-30]∙[ISIMatsuda]), and glucose
effectiveness by an OGTT-derived index (SgIO). ISIMatsuda (p <0.05), [δIRI0-30/δPG0-30], DIO and SgIO (both p <0.01),
but not QUICKI, 1/fasting IRI, or Stumvoll-1st and -2nd phases, were lower in the progressors at baseline. This
group was also characterized by the following: 1) ISIMatsuda, DIO and SgIO were reduced by 34%, 32% and 11%,
respectively (all p <0.01); 2) QUICKI and 1/fasting IRI diminished by 21% and 5%, respectively (both p <0.01); and
3) no significant changes were found in [δIRI0-30/δPG0-30], Stumvoll-1st and -2nd phases or BMI during the follow-up. In
the nonprogressors, no indices changed significantly during the follow-up. Our study concluded that during the transition
from normal glucose tolerance to non-diabetic hyperglycemia in this non-obese population, whole body insulin
sensitivity, hepatic insulin sensitivity, beta cell function, and glucose effectiveness were all attenuated, but no
significant changes in glucose-stimulated insulin secretion occurred. Also of note is the fact that the transition
took place without any accompanying increase in BMI.
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In obese subjects with normal glucose tolerance (NGT),
a lowering of insulin sensitivity (SI) during the develop-
ment of non-diabetic hyperglycemia (NDH) has com-
monly been observed (Faerch et al. 2009: Ferrannini
et al. 2011; Weyer et al. 1999). The picture with regard
to glucose-stimulated insulin secretion (GSIS), however,
has not been entirely consistent. In one previous study,* Correspondence: taizawax@ai-hosp.or.jp
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in any medium, provided the original work is pGSIS increased significantly in the nonprogressors but
decreased in the progressors (Weyer et al. 1999),
whereas other investigators found that, while the indi-
ces of beta cell function decreased, the total insulin
output over the 2 h of the oral glucose tolerance test
increased in the progressors (Ferrannini et al. 2011). A third
study reported no significant increase in GSIS in either the
nonprogressors or progressors (Faerch et al. 2009).
In Japan, subjects in the general population are largely
non-obese. Diabetes without overt obesity is common
(Matsuba et al. 2012), and it is possible that the naturalan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Japanese is different from that in obese populations
(Faerch et al. 2009: Ferrannini et al. 2011; Weyer et al.
1999). Cross-sectional studies have shown that SI and
GSIS were significantly attenuated in Japanese subjects
with minute elevations of plasma glucose (PG) within
the normal range, and the attenuation was progressively
greater with increasing levels of PG across NDH and
diabetes mellitus (DM) (Sato et al. 2002; Oka et al.
2012). However, there have been no reports of longitu-
dinal alterations in SI, GSIS or beta cell function (BCF)
during the progression from NGT to NDH in Japanese
subjects, or in any other non-obese population.
In a previous study, we found that the attenuation of
whole body SI and GSIS at baseline in Japanese subjects
with NGT was significantly related to a worsening of the
glucose metabolism (Oka et al. 2014a). Our next step
was to attempt to clarify the longitudinal changes in SI,
GSIS and BCF during the progression from NGT to
NDH. Because the attenuation of glucose effectiveness
(Sg) has been identified as an important element in the
worsening of the glucose metabolism (Goldfine et al.
2003; Tonelli et al. 2005), we also examined the longitu-
dinal changes in Sg by using an OGTT-derived index,
SgIO (Nagasaka et al. 2012).
Results and discussion
The baseline characteristics for the health examinees with
NGT whose immunoreactive insulin (IRI) was determined
at the follow-up OGTT were similar to those whose IRI
was not measured at the follow-up OGTT, except that the
subjects in the former group were slightly younger and had
slightly lower 2hIRI values. Importantly, the incidence rate
of NDH did not differ significantly between the two groups
(Additional file 1: Table S1). It was the examinees whose
IRI had been measured upon follow-up (n = 244) who be-
came the subjects of the present study.
At the end of the follow-up, 182 participants remained
in the NGT category and were classified as nonprogressors.
The rest had progressed to NDH or DM. Those who had
progressed to impaired fasting glucose (IFG) (n = 31) and
impaired glucose tolerance (IGT) (n = 28) were collectively
classified as progressors (n = 59), and the data from both
the nonprogressors and progressors were analyzed. The
subjects who progressed to DM (n = 3) were excluded from
the analysis.
The characteristics of the 241 subjects analyzed in this
study are shown in Table 1. Male gender and a family
history of diabetes were significantly more frequent in
the progressors than in the nonprogressors, and the
changes in fasting plasma glucose (FPG) and 2hPG in
male subjects were significantly greater compared to
those in female subjects (p = 0.04 for FPG and p <0.01
for 2hPG). At baseline, BMI, FPG, 2hPG and 2hIRI weresignificantly higher in the progressors than in the non-
progressors. On the other hand, ISIMatsuda, insulinogenic
index (δIRI0-30/δPG0-30), the product of insulinogenic
index and ISIMatsuda (DIOII), the product of Stumvoll-1
and ISIMatsuda (DIOST-1) and SgIO were significantly
lower in the progressors than in the nonprogressors at
baseline. During the follow-up, none of the indices in
the nonprogressors changed significantly. In the progres-
sors, ISIMatsuda, the quantitative insulin sensitivity check
index (QUICKI) and 1/fasting IRI (1/FIRI) decreased by
34%, 5% and 21%, respectively (all p <0.01). δIRI0-30/
δPG0-30 increased while Stumvoll-1 and -2 decreased
but in neither case significantly. The progressors also ex-
perienced attenuation of DIOII, DIOST-1 and SgIO by
32% (p <0.05), 32% (p <0.01) and 11% (p <0.01), respect-
ively, during the follow-up, with minimal, insignificant
decreases in BMI. Changes in ISIMatsuda and progression
to NDH were significantly correlated after adjustment
for age, gender, family history of diabetes, baseline BMI,
follow-up period and change in BMI in the entire popu-
lation (β = -0.15, p = 0.02).
When, at the end of the follow-up, a group-wise com-
parison was made between the nonprogressors and the
progressors, the absolute values for BMI, FIRI, and 2hIRI
were significantly higher, and ISIMatsuda, 1/FIRI, QUICKI,
δIRI0-30/δPG0-30, Stumvoll-1 and -2, DIOII, DIOST-1,
and SgIO significantly lower in the latter group (p <0.05
for Stumvoll-2 and <0.01 for other variables). Because
baseline values differed significantly for some variables
between the nonprogressors and the progressors, the de-
grees of change, i.e. the ratios, in the nonprogressors
and the progressors were also compared by Mann-
Whitney U test. FIRI and 2hIRI increased more signifi-
cantly in the progressors than in the nonprogressors and
ISIMatsuda, 1/FIRI, QUICKI, DIOII, DIOST-1 and SgIO
were more significantly attenuated in the nonprogressors
than in the progressors.
In this study, we aimed to clarify the longitudinal
changes during the development of NDH in Japanese
subjects, a non-obese population. The seminal findings
were as follows. In the progressors, ISIMatsuda, QUICKI,
1/FIRI, DIOII, DIOST-1 and SgIO were attenuated during
the follow-up, which was associated with insignificant
changes in δIRI0-30/δPG0-30, Stumvoll-1 and Stumvol-2.
In the nonprogressors, none of the variables showed sig-
nificant changes during the follow-up. Overall, our data
showed that an attenuation of hepatic and whole body
SI, BCF and Sg, on top of already lowered whole body
SI, early phase GSIS, BCF and Sg, took place during the
transition from NGT to NDH in this population. Among
the changes occurring during the development of NDH,
the lowering of whole body SI and BCF was the most
prominent, and the lowering of whole body SI and pro-
gression to NDH were independently correlated. Also of
Table 1 Characteristics of the participants analyzed in this study
Variables All Subgroup
Non-progressors Progressors
n 241 182 59
Age, yr 51(46–57) 50(45–57) 52(47–57)
Men/women 163/78 113/69 50/9§
Family Hx of diabetes, +/- 32/209 19/163 13/46‡
Baseline Follow-up Baseline Follow-up Baseline Follow-up
BMI, kg/m2 23.3(21.3–25.3) 23.2(21.3–25.4) 22.9(21.0–24.9) 23.0(20.9–25.0) 24.4(22.6–24.4) 24.2(22.8–26.0)
FPG, mg/dL 93(89–96) 94(90–97)† 92(89–95) 92(89–95) 95(91–97) 101(94–105)†
2hPG, mg/dL 104(93–116) 106(92–119)† 102(91–113) 103(90–114) 114(103–123) 134(109–155)†
FIRI, μU/mL 3.4(2.6–4.8) 3.6(2.8–5.1) 3.3(2.6–4.5) 3.4(2.7–4.6) 3.7(2.6–5.3) 4.4(3.6–5.8)†
2hIRI, μU/mL 19.3(12.3–29.6) 21.6(14.0–35.8)† 18.5(10.8–27.2) 19.5(13.4–32.2) 25.1(16.6–35.0) 31.9(19.9–49.5)†
ISIMatsuda 12.8(9.3–18.8) 11.5(7.5–16.4)† 13.2(10.2–19.4) 12.4(9.3–17.3) 11.1(8.3–17.8) 7.3(5.3–11.0)†
QUICKI 0.400(0.378–0.421) 0.396(0.376–0.417)* 0.400(0.380–0.424) 0.401(0.381–0.422) 0.393(0.372–0.420) 0.377(0.363–0.391)†
1/FIRI 0.29(0.21–0.38) 0.28(0.20–0.36) 0.30(0.22–0.39) 0.29(0.22–0.37) 0.28(0.19–0.40) 0.23(0.17–0.28)†
Insulinogenic index 0.61(0.36–1.10) 0.63(0.40–1.03) 0.65(0.39–1.12) 0.69(0.45–1.12) 0.48(0.29–0.90) 0.52(0.29–0.91)
Stumvoll-1 740.1(529.4–952.5) 753.2(571.3–1033.0) 755.5(561.7–967.4) 776.8(619.5–1030.3) 694.8(504.2–864.5) 638.2(448.7–869.8)
Stumvoll-2 205.2(161.6–251.8) 209.5(174.1–263.2) 206.8(168.4–252.8) 211.0(182.2–267.8) 199.0(155.3–236.5) 188.8(146.0–237.1)
DIO 7.78(4.38–15.52) 6.89(3.48–12.06) 8.73(5.27–17.2) 8.25(5.18–15.23) 5.16(3.28–9.33) 3.24(2.09–5.72)†
SgIo 3.27(2.87–3.88) 3.28(2.73–3.76) 3.41(2.93–3.97) 3.43(2.94–3.93) 3.04(2.65–3.65) 2.70(2.19–3.36)†
Ratio
ISIMatsuda 0.84(0.61–1.73) 0.96(0.64–1.31) 0.66(0.45–0.86)§
QUICKI 1.00(0.94–1.10) 1.00(0.96–1.05) 0.95(0.90–1.01)§
1/FIRI 0.97(0.71–1.79) 1.00(0.79–1.31) 0.79(0.58–1.06)§
Insulinogenic index 0.99(0.66–1.59) 0.99(0.68–1.58) 1.01(0.63–1.86)
Stumvoll-1 1.02(0.78–1.65) 1.03(0.80–1.31) 0.98(0.68–1.44)
Stumvoll-2 1.03(0.83–1.50) 1.03(0.84–1.23) 1.02(0.78–1.31)
DIO 0.88(0.45–1.61) 0.93(0.47–1.70) 0.68(0.37–1.27)‡
SgIo 0.99(0.91–1.05) 1.01(0.95–1.06) 0.89(0.78–0.96)§
Follow-up period, yr 3.3(2.2–4.1) 3.4(2.1–4.1) 3.1(2.2–4.7)
Numerical data is the median (25–75 percentile). Progressors comprise those who progressed to impaired fasting glucose and impaired glucose tolerance. BMI,
body mass index; FPG, fasting plasma glucose; 2hPG, PG 2-h after oral intake of 75 g glucose; FIRI, fasting immunoreactive insulin; 2hIRI, IRI after oral intake of
75 g glucose; ISIMatsuda, Matsuda insulin sensitivity index; QUICKI, quantitative insulin sensitivity check index; Insulinogenic index, δIRI0-30/δPG0-30; Stumvoll-1,
Stumvoll index of first phase insulin secretion; Stumvoll-2, Stumvoll index of second phase insulin secretion; DIO, oral disposition index (product of Insulinogenic
index and ISIMatsuda); SgIO, index of glucose effectiveness derived from OGTT. Ratio denotes [follow-up value/baseline value] of each variable in each subject.
*and †, p <0.05 and <0.01, respectively, compared to the corresponding baseline values by Wilcoxon’s signed rank test; ‡ and §, p <0.05 and <0.01, respectively,
compared to the corresponding values in nonprogressors by Fisher’s exact test or Wilcoxon’s signed rank test. See Text for detail.
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occurred in the absence of weight gain.
There are both similarities and dissimilarities between
our data and the data obtained in previous longitudinal
studies which analyzed the natural course of the devel-
opment of NDH in obese, WHO-defined NGT subjects
(Faerch et al. 2009: Ferrannini et al. 2011; Weyer et al.
1999). A lowering of SI in the progressors during the de-
velopment of NDH is a common finding in all studies
(Faerch et al. 2009: Ferrannini et al. 2011; Weyer et al.
1999; current study). On the other hand, the GSIS data
differ significantly (Faerch et al. 2009: Ferrannini et al.2011; Weyer et al. 1999; current study). In a study of
Pima Indians (Weyer et al. 1999), GSIS increased signifi-
cantly with attenuation of SI in the nonprogressors but
decreased in the progressors. In Europids, the indices of
beta cell function, such as glucose sensitivity, decreased
while total insulin output over the 2 h of the OGTT
increased slightly in the progressors (Ferrannini et al.
2011). In another study (Faerch et al. 2009), GSIS did
not increase significantly in either in the nonprogressors
or the progressors. The study subjects were markedly
(Weyer et al. 1999) or slightly (Faerch et al. 2009;
Ferrannini et al. 2011) obese, and the participants had
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ies (Faerch et al. 2009: Ferrannini et al. 2011; Weyer
et al. 1999) except ours (current study). The ‘hyperin-
sulinemia’ reported in one study (Weyer et al. 1999)
may partly have been a reflection of ‘hyperproinsuline-
mia’ caused by cross-reaction of IRI with proinsulin
(Larsson and Ahrén 1999). As far as we are aware,
there has been no longitudinal study in which Sg was
evaluated during the development of NDH. The
present study employed a recently reported index of Sg
derived from OGTT (Nagasaka et al. 2012), and is the
first documentation of a significant attenuation of Sg
with progression from NGT to NDH.
In summary, the major differences between the obese
subjects of previous studies and the non-obese subjects
in our study were as follows. In the former, there were
increases in GSIS in the nonprogressors (Weyer et al.
1999) and decreases in the progressors (Weyer et al.
1999). The indices of beta cell function decreased but
total insulin output over the 2 h of the OGTT increased
in the progressors (Ferrannini et al. 2011). Furthermore,
there was further weight gain in both the nonprogressors
and progressors in the obese subjects. In contrast, there
were no changes either in GSIS or body weight not only
in the nonprogressors but also in the progressors in the
non-obese population of our study.
A significant lowering of whole body SI occurred in
the progressors without weight gain. This suggested that
some factor other than weight gain must have been re-
sponsible for the lowering of SI in the progressors. Hep-
atic steatosis (Oka et al. 2014b; Burgert et al. 2006),
sarcopenia (Booth et al. 2012; Narici and Maffulli 2010)
and glucose toxicity (Solomon et al. 2012; Del Prato
et al. 1994) are all possible underlying mechanisms. The
reasons for male preponderance among the progressors are
unclear. However, this is compatible with the fact that
NDH is more prevalent in men than in women in the gen-
eral population (Matsuba et al. 2012; Cowie et al. 2009).
The study had its limitations. The sample size was
small and the OGTT data consisted of indices of mea-
surements. The follow-up period was not very long so
that the eventual disposition of the participants was un-
known. The number of subjects who developed NDH was
not very large and therefore a subanalysis after separation
of the progressors into IFG- and IGT-progressors was not
feasible. It is possible that the indices of insulin secretion
and insulin sensitivity may be different between IFG and
IGT even in non-obese populations and the circumstances
of the present study precluded the performance of a sub-
group analysis. The indices of SI, GSIS, BCF and Sg were
all functions of FPG and 2hPG by definition except for 1/
FIRI. In particular, determining BCF by applying DI from
OGTT is potentially problematic on account of autocorrel-
ation since both 1st-phase insulin secretion and ISIMatsudaemployed the same parameters of fasting glucose and fast-
ing insulin. Therefore, a degree of caution is called for when
interpreting the relationship between alterations in the
indices and changes in PG. Due to the study design, an
unintentional selection bias cannot be entirely ruled out.Conclusions
Diminution of whole body and hepatic SI, BCF and Sg
occurred during transition from NGT to NDH without
significant changes in GSIS or body weight in this popu-
lation. The unchanged GSIS might be an adaptation
failure for decreased SI. This may be a common feature
of non-obese populations in the early stage of worsening
of the glucose metabolism.Methods
Study sample
A retrospective observational study was conducted using
a dataset provided by the Health Service Department of
Hokuriku Central Hospital, where public school em-
ployees receive annual medical checkups. Out of an ini-
tial 604 consecutive subjects with NGT who received a
subsequent 75 g OGTT (Oka et al. 2014a; Yamauchi et al.
2013), 244 whose IRI was measured both at the basal
and subsequent OGTT before March 2012 (the median
follow-up period being 3.3 yrs), were selected for further in-
vestigation. All of them were Japanese. Signed informed
consent was obtained from all subjects, and the Hokuriku
Central Hospital Review Board approved the study
protocol.
We recommended measurement of IRI to the examinees
receiving OGTT, and 244 took up this option, which was
offered at an additional cost of approximately 10 euros. It is
possible, therefore, that there was an unintentional socio-
economic selection bias, i.e., that relatively wealthy people
were preferentially recruited. Nevertheless, if there were
any baseline phenotypic differences between those who ac-
cepted and those who declined our proposal regarding IRI
measurement, these differences were neglible (see below).Measurement of plasma glucose and insulin, and
diagnosis of glucose tolerance
PG was analyzed by the glucose oxidase method and IRI by
the chemiluminescence method (ADVIA Centaur, Siemens
Medical Solutions). The IRI assay does not cross-react
with proinsulin (Marcovina et al. 2007). IRI values
lower than the detection limit of the assay, 0.4 μU/mL
(n = 8), were assumed to be a half of the assay limit, i.
e., 0.2 μU/mL. The diagnosis of glucose tolerance cat-
egory was made according to the 2003 ADA criteria
(The Expert Committee on the Diagnosis and Classifi-
cation of Diabetes Mellitus 2003).
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ISIMatsuda was calculated as an index of whole body SI
using the fasting and 2 h blood samples: ISIMatsuda =
10,000/[sqrt(FPG∙2hPG∙FIRI∙2hIRI)] (DeFronzo and
Matsuda 2010) where FPG and 2hPG denote fasting PG
and PG 2 h after 75 g oral glucose load, and FIRI and 2hIRI
denote fasting and 2-h post load IRI, respectively. The
quantitative insulin sensitivity check index (QUICKI) (Katz
et al. 2000) and 1/FIRI (Hermans et al. 1999) were calcu-
lated as indices of primarily hepatic SI (Soonthornpun et al.
2003): QUICKI = 1/[log(FPG) + log(FIRI)]. For ISIMatsuda,
QUICKI and 1/FIRI, the unit of PG and IRI was mg/dL
and μU/mL, respectively (DeFronzo and Matsuda 2010;
Katz et al. 2000; Hermans et al. 1999). It should be noted
that 1/FIRI is not a function of PG values so that it is
free from any autocorrelation with FPG and 2hPG. As
an index of early phase GSIS, insulinogenic index
(δIRI0-30/δPG0-30) during 75 g OGTT, was employed
(Kosaka et al. 1974). As alternative indices of GSIS,
Stumvoll 1st (Stumvoll-1) and 2nd phase (Stumvoll-2)
indices, respectively, were also used: Stumvoll-1 = 1283 +
1.829∙IRI30 – 138.7∙PG30 + 3.772∙FIRI and Stumvoll-2 =
287 + 0.4164∙IRI30 – 26.07∙PG30 + 0.9226∙FIRI, in which
the unit of IRI and PG was pmol/L and mmol/L, respect-
ively (Stumvoll et al. 2000). BCF was estimated by oral dis-
position indices (DIO): a product of insulinogenic index and
ISIMatsuda (DIoII) (Nagasaka et al. 2012; Aizawa et al. 2012)
and a product of Stumvoll-1 and ISIMatsuda (DIoST-1) (Oka
et al. 2014a; Yamauchi et al. 2013) were employed. As an
index of Sg, SgIO which is derived from OGTT (Nagasaka
et al. 2012) was calculated. The degree of change for each
variable was quantified by calculating [follow-up data/base-
line data] ratio. Minus values for Stumvoll-1 and -2 were
obtained in 4 and 1 subjects, respectively, and δIRI0-30/
δPG0-30 could not be calculated in 13 subjects because the
numerator or denominator was zero or minus, and the
values for these subjects were assumed to be absent.
Statistics
SPSS version 21.0 was used for statistical analysis. Due
to non-normal distribution of the data, all numerical
data were expressed as median (25th - 75th percentile).
Mann-Whitney U test, Wilcoxon’s signed-rank test, Chi
square test and partial correlation were used as needed,
and p <0.05 was considered significant.
Additional file
Additional file 1: Table S1. Baseline characteristics of the NGT health
examinees who received and not received IRI measurement at the
follow-up OGTT.
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